Ueda, Kazuto
Sato, Yoshiaki
Shimizu, Shinobu
Suzuki, Toshihiko
Onoda, Atsuto
Miura, Ryosuke
Go, Shoji
Mimatsu, Haruka
Kitase, Yuma
Yamashita, Yuta
Irie, Keiichi
Tsuji, Masahiro
Mishima, Kenichi
Mizuno, Masaaki
Takahashi, Yoshiyuki
Dezawa, Mari
Hayakawa, Masahiro
Article History
Received: 19 January 2023
Accepted: 21 August 2023
First Online: 11 September 2023
Competing interests
: YS, SS, TS, MM, MH and MD declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: YS and SS have a collaborative research agreement for perinatal disease and an investigator-initiated clinical trial agreement supplying CL2020 free of charge for HIE with Life Science Institute Inc. (LSII). SS has a contract for consulting with LSII. YS, SS, TS, MM, MH, and MD have a patent for the application of Muse cells for the treatment of perinatal brain damage and other indications. MD is party to a collaborative research agreement with LSII. MD has a patent for the application of Muse cells for the treatment of cerebral infarction. MD holds patents for Muse cells and the isolation method thereof, which are exclusively licensed to LSII. KU, AO, RM, SG, HM, YK, YY, KI, MT, KM and YT declare no competing interests.